Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study
ConclusionsOur results suggest that sulfonylureas except for gliclazide increase the CRC risk in type 2 diabetic patients. Long-term follow-up studies are necessary to clarify the association of newer anti-diabetic medications with the CRC incidence.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Diabetes | Diabetes Type 2 | Endocrinology | Epidemiology | Fortamet | Glimepiride | Health Insurance | Insurance | Metformin | Study